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Abstract
Background: The use of mouse models to study human disease provides useful data that can provide support for
research projects or an existing drug discovery program. How well a model recapitulates the human condition
and the ease and reproducibility of data collected will determine how much confidence a scientist can place on
results obtained. Designing new treatments for rheumatic diseases, such as rheumatoid arthritis (RA), requires
complex immunocompetent models that depend on intricate cytokine networks. Using local cytokines, signal
transduction and transcription factor molecules as potential biomarkers to monitor disease and treatment efficacy
is the best method to follow the progression of tissue damage and repair when testing an unknown compound
or biologic. Described here in this report, a novel method for the non-enzymatic extraction and measurement of
cytokines and signal transducers and activators of transcription (STAT) molecules using Luminex® bead array
technology in two different mouse models for human RA - collagen antibody-dependent arthritis (CAIA) and
collagen-induced arthritis (CIA).
Results: Dynamic expression of several pro-inflammatory cytokines responsible for promoting disease
augmentation overtime were monitored, such as IL-1b, TNFa, IL-6 and IL-12, locally in the paws of affected animals
directly ex vivo. Local cytokine responses could be matched with serum cytokine levels and joint pathology results.
In addition, STAT1, 3, and 5a/b activation status could be monitored with confidence using specifically formulated
extraction buffer that protected the phosphorylation site. STAT3 activation followed paw swelling and cytokine
levels in both models and correlates of disease could be ablated upon treatment with dexamethasone. Here
reported a novel method of extracting joint fluid from the paws of inflamed mice coupled with powerful multiplex
bead technology allowing us to measure cytokine responses, pharmacodynamic markers such as STATs and
pharmacokinetic analysis of dosed agent all from the same sample directly ex vivo.
Conclusions: This method is powerful in that it is applicable to multiple autoimmunity model types, streamlines ex
vivo readouts in a high-throughput manner, and allows multiplexing providing the investigator with an array of
options and possible analytes when developing preclinical animal models to support drug discovery efforts in the
search for new treatments for rheumatic diseases.
Background
Rheumatoid arthritis (RA) is a debilitating disease that
results from chronic inflammation within the synovial
lining and lumen of multiple joints. Overtime this can
result in bone resorption and shortened life span among
those effected [1,2]. Using animal models to recapitulate
human disease is commonly employed to both study
disease mechanisms and for the discovery of new treat-
ments. One of the two most commonly used mouse
models for human RA is the acute antibody driven col-
lagen type II (CII) dependent inflammatory response
produced upon the intravenous (i.v.) transfer of anti-CII
antibodies, (i.e., collagen-antibody-induced-arthritis or
CAIA). The second and more physiological counter-part
model involves overcoming endogenous tolerance to
CII. Administration of self-protein, CII, along with an
adjuvant, heat killed Mycobacterium suspended in
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vides a powerful pro-inflammatory response driving
potent anti-CII CD4
+ T-cell helper-1 (Th1) and T-
helper-IL-17 (Th17) cellular and anti-CII antibody
responses. This model referred to as collagen-induced
arthritis (CIA) recapitulates several of the more com-
mon phenotypes observed in human disease such as
flares, chronic inflammation and bone resorption often
leading to rheumatoid arthritis [3].
Monitoring peripheral blood cytokine levels in these
models can be performed using various assays from ELI-
SAs to multiplex bead analysis. However, several studies
have clearly demonstrated the importance of studying
the local immune responses at the site of disease or insult
as being the most reflective of disease progression and/or
appropriate response for treatment [4-6]. The fundamen-
tal cornerstone of drug discovery is the ability to select a
viable target and being able to intercept that target as to
modulate disease activity in a specific fashion. Monitor-
ing local cellular and biochemical responses at the tissue
site of disease is crucial for predicting future disease out-
comes and thus drug treatment efficacy.
For CIA and CAIA models, local pro-inflammatory
cytokines and related signaling molecules and/or tran-
scription factors such as Signal Transducers and Activa-
tors of Transcription (STATs) parallel disease
progression [4,6]. Increases or decreases in such mole-
cules may predict treatment efficacy and rate of
response [5,7,8]. From this logic a novel methodology
was designed to sample external cellular milieu directly
from cryopreserved paws and limbs of arthritic mice
and quantitate trace cytokines and STAT activation (i.e.,
phosphorylation) directly ex vivo. Both molecular read-
outs followed the disease model and were predictive of
local responses. This method will provide the investiga-
tor with a way to follow cytokine responses with signal
transduction cascades and compound levels in a single
tissue from a single processed sample in a high-through-
put manner.
Methods
Animals
Mice used were Harlan DBA/1 mice (strain: DBA/
1OlaHsd). Mice were all aged matched, six to eight
weeks from start of experiment. All animals were main-
tained on a 24 hour light/dark cycle (on at 7 AM/off at 7
PM), with food and water available ad libitum.A l l
experimental animal procedures were approved by and in
accordance to the regulations of the Institutional Animal
Care and Use Committee (IACUC) of Cephalon, Inc.
Collagen-Antibody Induced Arthritis (CAIA) Model
Acclimated mice were randomized, pre-bled and mea-
sured for baseline inflammation before any studies were
initiated. On day 0, DBA/1 female mice were injected
i.v. with 100 μl of 1.5 mg of a 10 mg/ml cocktail arthri-
togeneic monoclonal antibodies directed against differ-
ent epitopes of collagen type II (Chondrex, Redmond,
WA) suspended in saline. On day 3, mice were injected
with 100 μlo f5 0μgo fE. Coli 0111:B4 (0.5 mg/ml
stock) LPS (Chondrex, Redmond, WA) i.p. and provided
with gel food during recovery. Two days post-LPS treat-
ment monitoring of arthritic paws began, peak arthritis
usually occurred 2-3 days following LPS treatment.
Before starting treatment mice were randomized,
grouped, scored, ear tagged and pre-bled to determine
baseline disease. Mice that exhibited a clinical score
greater than “1” in each limb were considered arthritic
and entered the study. Arthritis clinical score tables can
be found described elsewhere [3], briefly, score ‘0’ =n o
evidence of erythema and swelling; score ‘1’ = erythema
and mild swelling confined to the tarsus; score ‘2’
erythema and mild swelling extending from the ankle to
mid-foot; score ‘3’ erythema and moderate swelling
extending from the ankle to the metatarsal joints; score
‘4’ erythema and severe swelling encompass the ankle,
foot and digits. Treatment with Dexamethasone (Han-
na’s Pharmaceutical Supply, Wilmington, DE) at 1.5 mg/
kg was administered i.p. three times a week in saline,
vehicle consisted of saline alone. Dexamethasone treat-
ment continued from the peak of inflammation until the
end of the experiment. Mice were cheek bled for serum
sample collection for cytokines and antibodies through-
out the experiment. All samples were kept at -80°C until
ready to assay. At about 4 weeks mice were harvested
for spleen, plasma and arthritic paws for STAT and
cytokine quantitation and histological analysis. For ear-
lier validation studies we ended studies around 3-4
weeks post induction and removed paws at various dif-
ferent time points to measure cytokine levels overtime.
Collagen-Induced Arthritis (CIA) Model
Acclimated mice were randomized and pre-bleed and
measured for baseline inflammation before any studies
were initiated. On day 0, DBA/1 female mice were given
a primary immunization with equal volumes of bovine
collagen type II (CII), 2 mg/ml stock in 0.05 M acetic
acid, (Chrondrex, Redmond, WA) suspended in a CFA,
5 mg/ml (Chondrex, Redmond, WA) emulsion yielding
an injection of 100 μgo fC I Ia t1 0 0μli n t ot h eb a s eo f
the tail intradermally (i.d.). At day 21 post primary
immunization, the mice were rechallenged with CII
emulsified in IFA (Thermo Scientific, Rockford, IL) s.c.
on the flank of the mouse. On day 28 each mouse
received an i.p. injection of E. coli 0111:B4 (0.5 mg/ml
stock) LPS (Chondrex, Redmond, WA) at 10 μg in 100
μl of saline (25-50 μgo fL P Sw a sr e d u c e dt o1 0μgp e r
mouse to reduce mortality associated with endotoxic
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paw inflammation and disease. Before starting treatment
mice were randomized, grouped, scored, ear tagged and
pre-bled to determine baseline disease. Mice that exhib-
ited a clinical score greater than “1” in each limb was
considered arthritic and entered the study. Arthritis
clinical score was the same as that used to score CAIA
model. Treatment with Dexamethasone (Hanna’sP h a r -
maceutical Supply, Wilmington, DE) at 1.5 mg/kg was
administered i.p. three times a week in saline, vehicle
consisted of saline alone. Dexamethasone treatment
continued from the peak of inflammation until the end
of the experiment. Mice were cheek bled for serum
sample collection for cytokines and antibodies through-
out the experiment. All samples were kept at -80°C until
ready to assay. At about day 60 mice were harvested for
spleen, plasma and arthritic paws for STAT and cyto-
kine quantitation and histological analysis.
Histology
Front and hind paws (including carpus and tarsus) were
removed from the body of the animal. Skin from the
ends of the digits removed and the metatarsal region
skin perforated using surgical scissors to allow full dec-
alcification. Samples followed a decalcification procedure
using formic acid as described elsewhere [9,10]. After 7-
10 days of decalcification samples were washed for 2
hours in distilled water and stored in 70% ethanol at 4°
C until ready to be processed. Samples were paraffin
embedded, sectioned and stained with Haemalytoxin
and Eosin or Safranin-O stain. Safranin-O stain was per-
formed via manufacteurer instruction (Poly Scientific, R
+D). All histology work was performed at the Wistar
Institute (Philadelphia, PA). Images were collected using
an Olympus BX50 scope with an Olympus DP70 camera
and Olympus LabSens software (2009). A total of five
mice from each group were analyzed via histopathology,
representative images are shown for each group tested.
Western Blot Analysis
Samples were heated at 70°C for 10 minutes and loaded
onto a NuPAGE 10% Bis-Tris Gel, 1.5 mm, 15 well
(Invitrogen, no. NP0316BOX). The molecular weight
marker used was a BioRad Kaleidoscope prestained stan-
dard (BioRad, no. 161-0324). Run conditions were 150
volts for 1 hour at RT. Using a semi-dry transfer appa-
ratus (BioRad, no. 170-3940) proteins were transferred
into a nitrocellulose membrane. Primary antibody
diluted at 1:1000 in 5% milk for phosphorylated STAT3
pY705 (Cell Signaling, no. 9131) and total STAT3 (Cell
Signaling, no. 9132) diluted to 1:1000 in 5% BSA in TBS
were incubated overnight at 4°C with 5% milk in TBS
plus 0.05% Tween-20. Band sizes for STAT3a and
STAT3b are 79 kDa and 86 kDa respectively. Anti-
rabbit IgG, HRP-linked secondary antibody was used at
1:2000 (Cell Signaling, no. 7047). Detection was per-
formed using SuperSignal West Pico Chemiluminescent
Substrate (Pierce, no. 34077). Densitometry was per-
formed using GelPro analyzer 3.1 software.
Measurement of Serum Anti-Collagen type I and type II
autoantibodies
Serum was collected and stored at -80°C until use.
Thawed samples were analyzed by an in-house gener-
ated collagen type II and type I ELISA method. This
procedure can be found elsewhere [11], briefly each well
of a 96-well plate is coated with 50 μlo f5μg/ml of col-
lagen type I (Chondrex, no. 1006) or collagen type II
(Chondrex, no. 2016) in BBS (0.025 M Na2B4O7-10H2O,
0.01 M H3BO3, 0.075 M NaCl, pH 8.4) buffer overnight
at 4°C. Plates were washed with BBS plus 0.1% Tween-
20 three times before proceeding. Standard curves were
generated using purified mouse anti-collagen type I or
type II antibody, serum was added at 50 μlp e rw e l l ,
i n c u b a t e da tR Tf o r1h o u rt h e nw a s h e dw i t hB B Sp l u s
Tween-20. After washing, 50 μlo f1μg/ml of a rabbit
anti-mouse HRP-Fab fragment is added as a detection
antibody (Rockland, no. 811-1302) and incubated at RT
for 45 minutes. Plates were washed four times with BBS
plus Tween-20, then 100 μlo fT M Bs u b s t r a t ei sa d d e d
and the reaction is stopped using 100 μlo f1MH 2SO4.
The plates were read at 450 nM with a reference length
of 570 nM.
Measurement of Serum Cytokines via Multiplex Luminex®
Beads Assays
Frozen plasma at -80°C was thawed on ice, vortexed
then centrifuged for 10 minutes to remove debris and
aggregates. A total of 25-50 μlo fs e r u mw a su s e df o r
Luminex® assays following the manufacture’s instruction.
Ten different mouse cytokines were measured using the
m o u s ec y t o k i n e1 0 - p l e xb e ad kit (Invitrogen, no.
LMC0001). Briefly, filter plates (Millipore, no.
MAIPSWU10), were pre-wet with 200 μlo fw a s hs o l u -
tion (kit component) and 25 μl of beads were added per
well. Serum samples were diluted and a total volume of
50 μl was added per well (i.e., 25 μl of sample serum
plus 25 μl of assay diluent). Plates with beads were incu-
bated for 2 hours at RT on an orbital shaker in the dark.
At the end of the incubation the plate(s) were washed
twice in buffer, secondary biotinylated antibody was
added at a 1:10 dilution, 100 μl, in biotin diluent pro-
vided with the kit. Plates were incubated at RT for 1
hour in the dark then washed twice in buffer. Strepta-
vindin in assay diluent was added at 100 μlp e rw e l l ,
then incubated at 30 minutes at RT in the dark. Plate
was washed three times then we added 100 μlo fw a s h
solution and agitated the plate for 2-3 minutes at RT in
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xMAP 200 unit with data acquisition and analysis soft-
ware (Invitrogen, no. MAP0200). All bead washing was
performed using a vacuum manifold unit (Pall, no.
5017).
Measurement of Paw Cytokines and Phospho-STATs via
Multiplex Luminex® Bead Assays
The front (including carpus) and back (including tarsus)
right paws were collected and frozen in dry-ice cooled
isopentane and stored at -80°C until use. The paws were
c u tt o2m m×2m ms e g m e n t sa n dk e p to nd r y - i c ei n
round bottom polypropylene tubes (BD Falcon, no.
352059). Seven hundred microliters tissue extraction
buffer containing protease inhibitor cocktail (Calbio-
chem, no. 539136) and Halt phosphatase inhibitor cock-
tail (Thermo scientific, no. 78420) or Roche phosphatase
inhibitor cocktail (Roche, no. 04906837001) in tissue
extraction reagent I (Invitrogen, no. FNN0071) were
added to each sample. Samples were homogenized fro-
zen using a PT 10-35 Polytron homogenizer (VWR, no.
97036-082). After homogenization the sample was cen-
trifuged at 4°C for 2000 × g for 10 minutes, supernatant
was re-centrifuged at 4°C at maximum speed, 14,000 ×
g, for 15 minutes. Supernatants were carefully removed
to avoid picking up the top layer of lipids/adipose deb-
ris. Protein concentration was adjusted to 3 mg/ml
using a BCA protein assay (Pierce, no. 83228). A mini-
mum of 25 μlo ft h i se x t r a c t i o ni su s e di nt h ea b o v e
described protocol using the mouse cytokine 10-plex
bead kit (Invitrogen, no. LMC0001) or phophorylated
STAT1, 3, 5a/b, 3-plex kit (Invitrogen, LHO0005).
Compound quantification (PK, Pharmacokinetics)
Plasma and protein extraction from paw and spleen
samples were submitted for quantitative analysis to
determine the respective compound concentrations.
Blood samples were collected into heparinized tubes and
placed on wet ice until centrifuged (16,000 × g, 5 min-
utes) to separate the plasma. Supernatant was collected
and stored at -20°C pending analysis. At the time of
analysis, two volumes of cold acetonitrile containing an
internal standard (alprenolol) was added to each sample
which was then vortexed and centrifuged. The superna-
tant was removed, placed into an auto-sampler vial and
the amount of compound present in the samples was
analyzed by liquid chromatograph/mass spectrometry
(LC-MS-MS). The concentration of compound in the
samples was quantified against a mouse plasma standard
curve made via serial dilution in a concentration range
from 5 to 20,000 ng/mL. Samples containing concentra-
tions greater than 10% above the top of the standard
curve were diluted 1:10 with acetonitrile. The limit of
detection for plasma, paw and spleen were < 10 ng/ml.
Statistical Analysis
All ELISA or Luminex® assays were analyzed using lin-
ear regression curves to determine concentration of
analyte following data acquisition. Mann-Whitney non-
parametric, 2-way ANOVA or the Student’s t-test were
used for data analysis as noted in figure legends depend-
ing on the experiment and tested hypothesis. A p-value
less than 0.05 was considered significant. Statistical soft-
ware used was Graph Pad Prism (vs. 5.01, 2007), calcu-
lations were performed using Microsoft Office Excel
(Professional, 2003).
Results
Detection of Trace Cytokines in Two Models of
Rheumatoid Arthritis
Reproducing human disease in mouse models provides
the investigator with a reproducible and controlled sys-
tem whereby experiments can be performed rapidly to
test various reagents, therapeutics and methods. The
two most commonly used RA models for drug discovery
include the collagen type II antibody-induced arthritis
model (CAIA) and the more conventional collagen type
II-induced arthritis model (CIA). The CAIA model is a
great system to study human RA in a drug discovery
setting as it requires little set-up time and a meaningful
result can be obtained in only a few weeks. However,
one of the major disadvantages of using this model is
that since there is not a sufficient cellular anti-self
immune response generated, many of the classical RA
promoting cytokines are undetectable in the serum of
diseased mice [12,13]. Much of the immune response is
driven by antibody-dependent-cellular-cytotoxicity
(ADCC) at the site of disease, the synovial joint. Transi-
ent but significant cytokine accumulation would be
expected in the local tissue and possibly the draining
lymph node(s). For drug discovery efforts it is best to
chose a model that both recapitulates the human condi-
tion but also provides sufficient readouts in a relatively
short time frame. The modulation of pro-inflammatory,
disease-promoting cytokines, such as TNFa,I L - 1 b and
IL-12, using either biologics or small molecule inhibitors
is crucial to controlling RA, and many trials are still in
progress demonstrating this concept [14-17].
Since serum cytokines are difficult to measure using
this model [12,13] and since the most reflective disease
activity can be found locally in the paw [18] building an
extraction assay whereby cytokines are collected from
inflamed paws and read on a multiplex bead assay using
the powerful Luminex® technology would be greatly ben-
eficial. As illustrated in the method schematic flow chart
(Figure 1), front and back paws are collected and cut
into small pieces (2 mm × 2 mm) then snap frozen and
stored at -80°C until ready for processing. Keeping
everything on dry-ice, samples were homogenized and
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or phosphorylated STAT activation. Using Dexametha-
sone at 1.5 mg/kg body weight we were able to validate
our method modulating the local cytokine milieu using
a standard-of-care option, (i.e., glucocorticoid treat-
ment). Established arthritis was generated and glucocor-
ticoid, dexamethasone, was given three times a week,
i.p., and reduced paw swelling measured via a digital
caliper (Figure 2A, *p < 0.01) accompanied by a clinical
score (Additional file 1, Figure S1A). Body mass did not
change between treatment and vehicle group (Additional
file 1, Figure S1B). Early model optimization data was
collected but is not shown here for clarity. Serum cyto-
kine levels were inconsistent and in many cases unde-
tectable as expected (data not shown). However, using
this extraction method both early (Figure 2B, IL-1b) and
late (Figure 2C, IL-12) cytokines could be detected.
Cytokine IL-1b, one of the signature cytokines of RA
a n dat a r g e to fac o m m o n l yu s e dR At h e r a p e u t i c
[19,20], is found shortly after arthritis induction and can
be reduced upon dexamethasone treatment (Figure 2B,
*p < 0.05). Similar findings were found for IL-6 and IL-
1b using conventional RT-PCR methods (data not
shown). The source for IL-1b are usually activated
macrophage, dendritic cells and NK cells [21]. The
source for IL-12 are usually tissue activated macrophage
(F4/80
+) and dendritic cells but can also be made by
B-cells [22,23]. IL-12 is usually observed following early
innate cytokines including TNFa and IL-6 [24,25]. Cyto-
kines TNFa and IL-2 were also reduced upon dexa-
methasone treatment (Additional file 1, Figure S1C-D).
This reduction in inflammatory cytokines corresponded
with reduced inflammation and cartilage degradation as
demonstrated in paw histological H&E and Safranin-O
sections (Figure 2D).
This extraction method also works for the more con-
ventional CIA model where chronic arthritis provides an
array of cytokines that can be monitored both in the
peripheral circulation but also locally in the paw. Mice
immunized against collagen type II induce an inflamma-
tory cascade that is triggered and propagated by the
typical Th1/Th17-cellular response and involves cyto-
kines IL-6, IL-1b,T N F a,G M - C S Fa n dI L - 1 2[ 2 6 ] .D i s -
ease can be treated with the general standard-of-care,
dexamethasone, providing reduced paw swelling (Figure
3A), and clinical score (Additional file 2, Figure S2A)
without overt toxicity to the animal as shown by stable
body mass (Additional file 2, Figure S2B). Reduction of
circulating serum anti-collagen type II antibodies was
not observed nor correlated with disease treatment
Figure 1 Paw Cytokine Extraction Method Flow Sheet. As the illustration demonstrates, paws are selected for processing, snap frozen and
stored at -80°C until ready to be processed. When ready, samples are placed on dry ice and homogenized frozen using prepared tissue
extraction buffer. An aliquot is used for Luminex® cytokine analysis, phosphorylated STAT (pSTAT) pharmacodynamic (PD) Luminex® analysis and
another aliquot used for pharmacokinetic (PK) analysis. After all three analyses are finished; the PD data is compared to the functional cytokine
readouts. PK data should always be compared against the functional PD data to see if pharmacological saturation of the target has been
achieved. Thus, multiple cytokines and intracellular signaling molecules can be monitored using multiplex bead technology to better predict
local disease outcomes and help design more targeted therapies.
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and not the actual propagator of this disease (Additional
file 3, Figure S3). A significant drop in circulating serum
IL-12 using dexamethasone (Figure 3B) corresponds with
a reduced 60 day IL-12 level in the paws of affected ani-
mals (Figure 3C). Similar results were observed for spleen
(data not shown). In addition, consistent drop in IFNg
and IL-6 upon dexamethasone treatment (data not
shown) was also observed. The CIA model recapitulates
many of the common cytokine cascades that support dis-
ease augmentation and using our method we were able
to monitor cytokine levels increasing and decreasing
overtime in the paw in a much more dynamic manner
than observed in the serum (Additional file 4, Figure S4).
As expected IL-1b starts low at the beginning of disease
and as disease progresses IL-1b levels surge only to drop
later as the disease begins to resolve (Additional file 4,
Figure S4). A spike of IL-10 is observed early in disease
possibly due to latent activated macrophage [27] followed
by a consistent elevated level of IL-6 cytokine as expected
[28]. An unlikely result is the low expression of GM-CSF
and TNFa in the paw of CIA mice (Additional file 4, Fig-
ure S4). Histology results mirror expected responses as
indicated by the high levels of cytokines found in the paw
and serum further validating our paw cytokine extraction
method (Figure 3D).
Sensitive Detection of Phospho-STAT3 Activation in Paws
of Arthritic Mice
What is better than the detection of extracellular mole-
cules involved in driving the deleterious immune
response liable for observed tissue damage is actually
monitoring and measuring the levels of signaling mole-
cules and transcription factors involved in generating or
supporting these cytokine cascades. Measuring STAT
proteins necessary to transduce signals from several
c y t o k i n er e c e p t o r ss u c ha sI F N gR( e . g .S T A T 1 ) ,I L 6 R
(e.g. STAT3) and IL-2Rb/gc (e.g. STAT5a/b) provides
the investigator with a way of monitoring developing
disease activity and can better support drug discovery
efforts by homing in on key cascades. However, it is
important to note that several different cytokine recep-
tors may converge on a single STAT transcription factor
pathway and are not limited to these particular STATs
and the converse is true that a single cytokine receptor
may activate more than one STAT [29].
To compare our multiplex bead method to the con-
ventional western blot analysis we ran inflamed paw
extracts from CAIA mice on a western blot side-by-side
with the multiplex bead assay measuring phosphorylated
STAT1 (pSTAT1), STAT3 (pSTAT3) and STAT5a/b
(pSTAT5a/b). Both pSTAT1 and pSTAT5a/b were simi-
lar to the vehicle only group (data not shown), however,
pSTAT3 showed a dramatic change from vehicle control
Figure 2 Paw Cytokines Follow Disease Progression in CAIA
Mouse Model. Female DBA/1 mice were injected i.v. with anti-
collagen type II antibodies and given a LPS booster injection three
days after the antibody transfer. This combination of antibodies and
adjuvant provides a potent and rapid, but self-limiting, antibody
dependent arthritis. (A) Disease is established and mice enter the
study when specific criteria are met (see materials and methods).
Dexamethasone significantly reduced mean paw thickness
(averaged from individually measured paws - front, back, right and
left), *p < 0.01 versus vehicle control group, N = 10 per group.
(B) Paw IL-1b concentration sampled in 3 mg of total protein
prepared as described in the materials and methods. As expected
from the paw swelling, dexamethasone reduces cytokine levels
compared to the vehicle control group, *p < 0.05. (C) Paw IL-12
slowly increases overtime as disease progresses, dexamethasone
treatment significantly reduces paw cytokine levels, *p < 0.05, N = 5
per group. (D) Histological analysis of paw swelling using H&E and
Safranin-O stains (carpus shown). Vehicle shows leukocytic infiltrates,
matrix degradation and osteolysis, dexamethasone treated mice
compared to non-diseased animals (data not shown), N = 5 mice
per group, representative images shown, 4× magnification. All
graphs show Mean ± SEM.
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tern blot (Figure 4A-B; only pSTAT3 data shown).
Lanes represent two independent samples from each
group, densitometry analysis results are shown below
the blot. Comparing these results (Figure 4A) to the
multiplex bead results (Figure 4B) the bead array pro-
vides better data resolution and a lower and more
reproducible background. Although, results are compar-
able between the two methods, the Luminex® data pro-
vides greater statistical significance due to the larger
signal to noise ratio. However, the bead array provides
the ability to simultaneously measure several different
STAT molecules in a single high-throughput manner.
Similar results were observed for the spleen tissue but
were not as robust as the paw where most of the disease
activity is confined (data not shown).
Using the CAIA model significant decrease in the level
of pSTAT3 as early as 4 hours after dexamethasone
treatment (Figure 5A) could be observed, however no
significant change in pSTAT5a/b levels were ever
observed, albeit a trend decrease does support the case
of dexamethasone acting as a general immunosuppres-
sant (Figure 5B). As shown by pharmacokinetic analysis,
dexamethasone can be detected in the paw as early as 2
hours post-injection and can affect downstream effector
cascades (Figure 5C). This suggests that similar thera-
pies can be used with this reference standard of care
(SoC) agent to monitor cytokine pathway modulation in
conjunction with disease as exemplified in Figures 2.0
and 3.0. Similar pSTAT results were also obtained for
the CIA model (Additional file 5, Figure S5) for both
pSTAT3 and pSTAT5, no change in pSTAT1 was
observed in any model tested (data not shown).
Discussion
Here we discuss a novel, yet simple, method to extract
tissue cytokines and transcription factors from the paws
of mice with rheumatoid arthritis. Cytokines play a
major role in the development of arthritis, especially at
the site of initial insult, the synovial joint. Ex vivo end
analyses of sectioned joints only give a snap shot of
active cytokine and signaling pathways and many anti-
gens are destroyed in the processing of these tissues.
Our extraction method provides the investigator with a
means to measure native proteins in their active confir-
mation without the addition of exogenous treatments.
In addition, using various phosphatase and protease
inhibitors we are able to detect endogenously activated
phosphorylated STATs that correlate well with disease
activity and treatment. This method will be useful for
following treatment with a small molecule inhibitor or
biologic modulating cytokine pathways.
Western blots are extremely useful for the detection of
trace proteins; however, one of the major limitations is
Figure 3 Paw Cytokines Follow Disease Progression in CIA
Mouse Model. Female DBA/1 mice were injected i.d. at the base of
the tail with collagen II plus CFA, followed by a booster s.c. on day
21 with IFA followed by a 28 day LPS priming, full onset of arthritis
was between 30-35 days. (A) Disease is established and mice enter
the study when specific criteria are met (see materials and
methods). Dexamethasone treatment at 1.5 mg/kg given i.p. three
times a week significantly reduced paw thickness (average from
independently measured mice) compared to vehicle control mice,
*p < 0.05, N = 10 mice per group. (B) Serum IL-12 levels were
significantly reduced upon dexamethasone treatment as compared
to vehicle control group, *p < 0.05. (C) Paw IL-12 levels were
assessed by our Luminex® extraction protocol. IL-12 levels measured
at the final time point were significantly less in the dexamethasone
treated mice as expected from reduced serum IL-12 levels, *p <
0.05. (D) Histopathology H&E and Safranin-O representative slides
from five mice (tarsus shown) at 4x magnification show that
dexamethasone treated mice have reduced inflammation, matrix
degeneration and joint disfiguration compared to the control
vehicle mouse. All graphs show Mean ± SEM.
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fluorescent western blots multiple proteins can be
observed on a single membrane using different fluoro-
chromes and excitation channels. Quantitative RT-PCR
is also an option; however, for the average drug discov-
ery scientist running hundreds of ex vivo samples
becomes tedious and time consuming. Multiplex bead
array technology has advanced to provide the researcher
Figure 4 Using Luminex® Multiplex Bead Arrays to Measure
Intracellular PD Markers is More Sensitive than Conventional
Western Blot Analysis. Using the 60 day CIA mouse paws we
extracted the paw supernatants as described in the materials and
methods and tested for phospho-STAT3 using either conventional
western blot analysis with densitometry or multiplex bead analysis.
(A) Extracts from two different mice per group were run on a SDS-
PAGE gel and transferred onto a nitrocellulose membrane and
exposed to film for the final image. Western blot was probed with
anti-pSTAT3 a (79 kDa) and b (86 kDa) subunits, stripped then re-
probed for total STAT3, a (76 kDa) and b (86 kDa) subunits as
shown. Below graph shows densitometry analysis from above blot
**ns p = 0.2037 versus vehicle, *ns p = 0.1226 versus CIA + vehicle
group, N = 3 per group shown. (B) Luminex® phospho-STAT kit
analyzed paw extractions from CIA mice treated with vehicle alone
or dexamethasone. Samples were those same as used for the W.
blot above, *p = 0.034 compared CIA + vehicle group, **p = 0.017
compared to vehicle alone. For both graphs, statistical test used for
p-values: two-tailed paired Student’s t-test, N = 3-4 mice per group
shown. All graphs show Mean ± SEM, ns = not significant.
Figure 5 Specific Reduction of pSTAT3, but not pSTAT5 in
Dexamethasone Treated CAIA Mice Overtime Corresponds with
Local Dexamethasone Pharmacokinetics. Using our CIA mouse
model of RA we treated 35 day mice with either vehicle alone or
dexamethasone and looked overtime at the loss of pSTAT3 and
pSTAT5 in the paws using our extraction method. (A) Paws from
treated mice were processed and analyzed using Luminex®
technology, rapid decrease in pSTAT3 observed within 4 hours post
dexamethasone treatment and remains decreased as shown for the
6 hour time point compared to vehicle alone, *p < 0.05. (B) No
significant change observed for pSTAT5, trend decrease in overall
pSTAT5 levels, ns = not significant as compared to vehicle alone. (C)
PK of dexamethasone in the plasma, spleen and paw extracts from
treated mice, see materials and methods for complete methods for
PK analysis. All graphs show Mean ± SEM, N = 4 mice per group.
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phospho-STAT proteins we have recently expanded to
include the detection of signaling molecules such as Akt
and protein kinase C (PKC), also molecules involved in
the immuno-proteasome pathway. This means that it is
possible to use this extraction method coupled with
multiplex bead arrays for different disease models. One
example is to use this method for studying lupus arthri-
tis in the MRL/lpr mouse model for rapidly developing
lymphoproliferative disease [30]. Several phenotypes of
human systemic lupus erythematosus (SLE) are repro-
duced in the commonly used New Zealand Merged
(NZM) and MRL/lpr (Fas
lpr) models [31,32]. Dermatitis,
lupus arthritis and lupus nephritis are some of the most
common lupus-related symptoms observed in these sys-
tems [33]. Thus a possible alternative use for this
extraction method is the ability to measure various cyto-
kines and signaling molecules within the same sample
from all three affected regions of the lupus-prone animal
- joints (lupus arthritis), skin (dermatitis) and kidneys
(lupus nephritis).
Paw swelling is slowly reduced by dexamethasone in
the CAIA model as expected, however, paw IL-1b and
IL-12 does not significantly decrease below vehicle until
days 9 and 10 respectively (Figure 2). Since paw swelling
is significantly reduced below that of vehicle by day 9 it
is expected that this reduction is in due part to these
reduced cytokine levels. The molecular signaling events
for this change can be observed using both Western
blot and Luminex® cytokine beads, however, due to the
lowered sensitivity of Western blots a significant result
using the multiplex bead method is lost, using Western
blots, due to signal strength heterogeneity (Figure 4).
Many of the expected cytokines are raised during
arthritis in this model, such as IL-1b, IL-10 and IL-6,
however, unexpectedly both GM-CSF and TNFa remain
low (Additional file 4, Figure S4). GM-CSF being a sur-
vival and growth factor for several haematopoietic cells
especially for granulocytes and monocytes, we would
expect an increase in paw expression overtime. Exogen-
ous GM-CSF and TNFa have both been shown to
induce arthritis in mice [34,35]. This particular study
provides a limited view and is intended to give the
reader an idea of how paw cytokines could be followed
overtime using this multiplex technology and is not
intended to be a guide. Upon multiple repeats we would
expect some heterogeneity but that both TNFa and
GM-CSF should remain elevated in the swollen paw.
Another unexpected result was the failure of dexa-
methasone treatment to reduce the levels of circulating
anti-collagen type II (CII) antibodies below that of vehi-
cle (Additional file 3, Figure S3). High dose dexametha-
sone can induce lymphocyte apoptosis, hence the use of
high dose dexamethasone for the treatment of multiple
myeloma [36]. This failure to reduce anti-CII antibodies
can be explained by the fact that mouse IgG has a very
long plasma half-life (t1/2~28 days). Dexamethasone
treatment of paw swelling may also reduce the levels of
circulating antibody secreting cell types but impact on
circulating anti-CII IgG may not be observed until sev-
eral months post-treatment.
One consistent observation that was noticed between
the models was the general lack of pSTAT5a/b or
pSTAT1 activation over vehicle alone (data not shown).
All three STAT molecules were measured including
STAT5a/b, STAT1 and STAT3. STAT molecules are
becoming more popular with their essential role in auto-
immunity, cancer and even central nervous system
(CNS) disorders [6,37-39]. STAT molecules are unique
in that they can act as signaling molecules, transcription
factors, have been shown to interact with NFB and sta-
bilize performance and now there is accumulating evi-
dence that there are mitochondrial STAT molecules
responsible for interacting with the electron-transport
system and adenosine triphosphate (ATP) synthesis via
interaction with Ras [38,40,41]. As for our observations,
in these models, we would have expected to see STAT3,
STAT-4, STAT5a/b and STAT1 activation as these
molecules are downstream of the IL-6 (IL-6a/GP130),
IL-12 (IL-12Rb), GM-CSF (GM-CSFRa/b), and IFNg
(IFNgR1/2) receptors respectively. The presence of IL-12
in the paws was not surprisingly unusual as the CIA
model is mainly driven by typical Th1 responses and IL-
12 helps support the signal for T-bet expression and
Th1 cell differentiation [42-44]. Cytokines IFNg and IL-
6 also increased with disease and could be reduced
upon dexamethasone treatment (data not shown). It is
quite possible that the source of IFNg are Th1 cells or
NK cells while IL-6 is most likely provided by activated
macrophage. It is this IL-6 autocrine cycle that is most
probably responsible for the high levels of pSTAT3
observed in the paws of affected animals. The ability of
dexamethasone to decrease intrinsic pSTAT3 levels and
several cytokines is most likely due to simply less
inflammation as observed by reduced mean paw size
and clinical score. Dexamethasone, member of the glu-
cocorticoid steroid family, is known to work via several
mechanisms including the rapid upregulation of new
IBa preventing NFB activation and nuclear transloca-
tion [45], eventually leading to immunosuppression.
Dexamethasone is commonly used to treat various auto-
immune indications including rheumatoid arthritis (RA)
and SLE; in addition dexamethasone may also be used
to treat various hematological malignancies [46-48].
As expected, the two models produced similar but not
completely overlapping cytokine cascades in the affected
paws. The CAIA model is more dependent on the
actions of tissue antibody-dependent cell cytotoxicity
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innate cytokines dominate such as IL-1b and TNFa (fig-
ure 2 and data not shown). Cytokine IL-12 levels slowly
increase as macrophage and dendritic cells (DCs)
mature with disease progression (Figure 2C). As for the
CIA model which is more dependent on typical Th1/
Th17 responses further activating synovial macrophage,
high levels of paw IL-12 (Figure 3C) along with the clas-
sical early innate cytokines such as IL-1b (Additional file
5, Figure S5A) and IL-6 (Additional file 5, Figure S5A
and B) are also observed.
Conclusions
In summary, we have developed a novel method of
extracting and protecting cytokines and related signaling
molecules from degradation and coupled it to multiplex
bead arrays where by multiple potential biomarkers can
be monitored simultaneously from the same sample
directly ex vivo. This method is more streamlined and
time-efficient than several conventional methods such as
western blot analysis or RT-PCR, measures molecules in
their native, non-reduced form, and can be coupled to
ex vivo pharmacodynamics (PD) and pharmacokinetic
(PK) analyses. This method may be applied to lupus
models, various different organ types, such as the kid-
neys, and even tumor xenograft models. This method
will help contribute to the understanding of how
dynamic cytokine cascades at the site of disease in
arthritis may aid in the discovery of new compounds or
biologics with the potential to modulate local deleterious
immune responses.
Additional material
Additional file 1: Clinical Score and Body Mass of CAIA Mice
Treated with Dexamethasone. Female DBA/1 mice injected with
arthritogenic antibodies and LPS develop RA and begin treatment by
day 6. (A) Total clinical score of mice treated with vehicle or
dexamethasone, three times a week. Clinical score definitions can be
found in the materials and methods. N = 10 per group, *p < 0.001,
Mann-Whitney, two-tailed test. (B) Mean body mass of all mice treated,
no significant difference observed between any group, N = 10 mice per
group. All graphs show Mean ± SEM. (C) Paw IL-2 and (D) TNFa
concentration sampled in 3 mg of total protein prepared as described in
the materials and methods *p < 0.05.
Additional file 2: Clinical Score and Body Mass of CIA Mice Treated
with Dexamethasone. Female DBA/1 mice were induced to develop
CII-dependent arthritis using purified bovine CII with CFA and boosted
with CII in IFA, then later primed with LPS to provide an acute local
response in the joints of affected mice by day 30 after initial
immunization. (A) Total clinical score shown, dexamethasone treatment
was provided three times a week at 1.5 mg/kg, *p < 0.01, Mann-Whitney,
two-tailed test, N = 10 mice per group. (B) Mean body mass of all mice
treated, no significant difference observed between any group, N = 10
mice per group. All graphs show Mean ± SEM.
Additional file 3: Serum Levels of Anti-Collagen type II
Autoantibodies in CIA Model. Serum IgG anti-collagen type II
autoantibodies were measured by ELISA as described in the materials
and methods. No significant change was observed at any time point, N
= 4 mice shown, graph shows Mean ± SEM.
Additional file 4: Paw Cytokine Levels in the CIA Model during
Disease Development. Female DBA/1 mice were induced to develop
CII-dependent arthritis using purified bovine CII with CFA and boosted
with CII in IFA, then later primed with LPS to provide an acute local
response in the joints of affected mice by day 30 after initial
immunization. Age matched female DBA/1 mice were either not induced
(0 wk time point) or induced to develop CIA by week 4. Paws from each
week were removed from CIA mice and cytokines were measured using
our extraction method coupled with Luminex® to generate the graph
shown.
Additional file 5: Specific Reduction of pSTAT3 and not pSTAT5 in
Dexamethasone Treated CIA Mice. Sixty day inflammed CIA mouse
paws were processed and analyzed using Luminex® kits for the presence
of activated pSTAT3 and pSTAT5. (A) Reduction in paw levels of pSTAT3
observed after three rounds of Dexamethasone treatment, 1.5 mg/kg, *p
< 0.05. (B) Lack of pSTAT5 reduction observed in dexamethasone treated
mice similar to what is observed in the CIA model. All graphs show
Mean ± SEM, N = 3-4 per group.
Abbreviations
(CIA): Collagen-induced arthritis; (CAIA): Collagen-antibody induced arthritis;
(RA): Rheumatoid Arthritis; (CII): Type II Collagen.
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